KYMR

#919
Kymera Therapeutics, Inc. - Common Stock
117.6 2 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
116.28
118.55
Intervallo Annuale
55.66
130.05
Variazione giornaliera
-1.00%
Variazione Mensile
+14.45%
Variazione di 6 mesi
+31.80%
Variazione Annuale
+99.02%
Chiusura Precedente
118.8 1
Open
116.9 2
Minimo
116.2 8
Massimo
118.5 5
Volume
72
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Kymera Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Kymera Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Kymera Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Kymera Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Kymera Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Kymera Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Kymera Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Kymera Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Kymera Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Kymera Therapeutics, Inc. current report, Q1 FY2026
8-K

Kymera Therapeutics, Inc. current report, Q2 FY2026

Full document

Kymera Therapeutics, Inc. (KYMR) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K covers the Annual Meeting of Shareholders held by Kymera Therapeutics, Inc. on June 24, 2026. The filing details the voting results for three proposals submitted to shareholders, as previously outlined in the Proxy Statement filed on April 29, 2026.

Key Financial Metrics

This filing is a corporate governance report regarding shareholder voting results. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial performance details.

Material Changes and Voting Results

The following proposals were voted upon and approved by shareholders:

  • Proposal 1: Election of Class III Directors
    • Bruce Booth, D.Phil.: 71,962,459 For; 5,430,527 Withheld.
    • Nello Mainolfi, Ph.D.: 73,411,316 For; 3,981,670 Withheld.
    • John Maraganore, Ph.D.: 72,501,958 For; 4,891,028 Withheld.
    • Elena Ridloff, CFA: 72,453,404 For; 4,939,582 Withheld.
    • All nominees were elected to three-year terms ending in 2029.
  • Proposal 2: Advisory Vote on Executive Compensation
    • Shareholders approved the compensation of Named Executive Officers.
    • Results: 74,903,687 For; 2,462,732 Against; 26,567 Abstain.
  • Proposal 3: Ratification of Independent Auditor
    • Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
    • Results: 79,043,801 For; 38,128 Against; 18,233 Abstain.

Guidance, Outlook, and Risks

This filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the outcomes of the shareholder vote.

Key Facts for Investor Verification

  • Verify the terms of the newly elected Class III directors (Bruce Booth, Nello Mainolfi, John Maraganore, Elena Ridloff) and their tenure through 2029.
  • Confirm the level of shareholder support for executive compensation (approximately 96.8% voted For).
  • Note the strong ratification of Ernst & Young LLP as the auditor (approximately 99.5% voted For).
  • Review the April 29, 2026 Proxy Statement for detailed biographies of directors and specific compensation metrics referenced in Proposal 2.

Notizie